GlassScriptPhysician profile
Steven D Pritchett
NPI 1225084197
$3,768.72
in general payments reported to CMS, 2019-2025
32 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $423 · 2021: $651 · 2022: $679 · 2023: $777 · 2024: $454 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.53 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $808.98 | 2021-2025 | |
| Pfizer INC. | $292.05 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $246.31 | 2019-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $245.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $212.97 | 2019-2023 | Eliquis |
| Novo Nordisk INC | $179.99 | 2020-2025 | Rybelsus, Ozempic |
| Amgen INC. | $169.05 | 2021-2025 | Otezla, Repatha, Otezla |
| Allergan, INC. | $134.33 | 2020 | |
| Abbott Laboratories | $133.36 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $120.44 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.57 | 2020-2024 | Xifaxan |
| Dexcom, INC. | $107.53 | 2021-2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $106.32 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.27 | 2019-2023 | Trintellix |
| Glaxosmithkline, LLC. | $100.35 | 2019-2024 | Arexvy, Shingrix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $98.41 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $97.65 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.75 | 2019-2023 | Tradjenta, Synjardy, Jardiance |
| Exact Sciences Corporation | $54.87 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $53.45 | 2019-2024 | |
| Seqirus USA INC | $50.13 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Lundbeck LLC | $38.54 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $36.17 | 2023 | Gemtesa |
| Aimmune Therapeutics, INC. | $32.22 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.26 | 2022 | |
| Nestle Healthcare Nutrition INC. | $26.94 | 2022-2023 | |
| Astellas Pharma US INC | $18.19 | 2023 | Myrbetriq |
| Radius Health, INC. | $17.27 | 2025 | Tymlos |
| Optos, INC. | $17.14 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.88 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.53 | 2021 | |
| Merck Sharp & Dohme LLC | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Pritchett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.